Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Ozone Targets Five Half-Price Generics For Indian Market

This article was originally published in PharmAsia News

Executive Summary

Ozone Group says it plans to bring to India's market in July five drugs it will price at half the cost of what already is available. Ozone is one of a group of Indian pharmas seeking to counter an influx of questionable branded drugs into India by offering cheaper generics. Ozone's plans are focused on five drugs - an antibiotic and drugs to treat diarrhea, ulcers, pyretic and a painkiller. The firm's chairman and managing director. S.C. Sehgal, said the intent is to make available cheaper drugs with no sacrifice of quality, so he does not expect to garner major revenues from the drugs. (Click here for more

You may also be interested in...

Biden COVID-19 Plan Would Grow Domestic Manufacturing Base

The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.

People On The Move: Appointments At Sanofi, Enzymatica And Bayer

Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.

Trust, Innovation And Growth – Three Priorities For The Global Self-Care Industry In 2021

The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts